Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Arm 1 - GEH120714 (18F) Injection, Arm 1- GEH120714
GEH120714 · 1 trial · 1 indication
Record the occurrence of adverse events (AEs) to evaluate the safety of a single dose of GEH120714 (18F) Injection in healthy volunteers (HV) and participants with rrMS.
| Arm | Type | Description |
|---|---|---|
| Arm 1 - GEH120714 (18F) Injection | EXPERIMENTAL | Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration). |
| Name | Type | Description |
|---|---|---|
| Arm 1 - GEH120714 (18F) Injection | DRUG | Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration). |
Inclusion Criteria: Inclusion Criteria for all Participants: * The subject has a clinically normal or acceptable medical history and physical examination at screening. * The subject has an acceptable kidney function (eGFR \>60 mL/min/1.73m2) for administration of Gadolinium. * The subject has a tr...
GEH120714 is an investigational small molecule imaging agent developed by GE HealthCare Technologies Inc. (ticker GEHC). It is being studied as an 18F-labeled injection for use in relapsing-remitting multiple sclerosis (rrMS). It is a Phase 1 candidate and has not been approved by the FDA.
GEH120714 is being studied in relapsing-remitting multiple sclerosis (rrMS) as an imaging agent. The Phase 1 trial assessed its safety, bio-distribution, radiation dosimetry and imaging protocol in healthy volunteers and participants with rrMS. It is investigational and is not an approved treatment for rrMS.
GEH120714 is developed by GE HealthCare Technologies Inc., which trades under the ticker GEHC. The company sponsored the Phase 1 study of the agent in healthy volunteers and participants with relapsing-remitting multiple sclerosis.
GEH120714 is in Phase 1 development. Its only listed trial, NCT01738347, is a completed Phase 1 study. The drug is investigational and has not been approved by the FDA for any indication.
GEH120714 has been studied in one clinical trial, NCT01738347, a completed Phase 1 study titled to assess safety, bio-distribution, radiation dosimetry and imaging protocol optimization. It enrolled 30 participants, including healthy volunteers and people with relapsing-remitting multiple sclerosis, and was conducted in Canada.
Yes. GEH120714 is also referred to as GEH120714 (18F) Injection and Arm 1 - GEH120714 (18F) Injection. These names refer to the same investigational imaging agent developed by GE HealthCare Technologies Inc. for study in relapsing-remitting multiple sclerosis.